← Research library

Oral Ovagen in chronic hepatitis and after chemotherapy

Comparison in people · 2011

What was studied
40 receiving adjunctive Ovagen (20 with persistent chronic hepatitis, 20 after chemotherapy) and 34 usual-care controls. The treated series was aged 38–67.
Main finding
In the chronic-hepatitis table, bilirubin was 28.4 µmol/L before treatment, 21.5 after adjunctive Ovagen and 26.4 after usual care. ALT and IgM were marked lower than baseline in both groups.

Reported findings and study design

Adjunct-use comparison of 40 treated and 34 usual-care controls. The outcome tables below concern chronic hepatitis. The reported oral course was 15–20 days in the group description.

Population or model 40 receiving adjunctive Ovagen (20 with persistent chronic hepatitis, 20 after chemotherapy) and 34 usual-care controls. The treated series was aged 38–67.

Dose, route and schedule

The group methods describe two 0.100 mg capsules twice daily before meals for 15–20 days, alongside usual care. The introduction gives a broader tablet schedule of one to two twice daily for 10–20 days.

Protocol source ↗ · Russian commercial reproduction of the 2011 institute report, methods and Tables 1–3

Results · Russian commercial reproduction of the 2011 institute report, methods and Tables 1–3
MeasureResultComparison, timing and statistics
Total bilirubin21.5 vs 26.4 µmol/LOvagen plus usual care versus usual care. Shared baseline column 28.4 µmol/L. · Ovagen result marked p < 0.05 versus baseline.
ALT41.4 vs 44.3Ovagen plus usual care versus usual care. Shared baseline column 50.2. The table has a garbled unit label. · Both post-treatment results marked p < 0.05 versus baseline.
IgM2.1 vs 2.5 g/LOvagen plus usual care versus usual care. Shared baseline column 3.6 g/L. · Both post-treatment results marked p < 0.05 versus baseline.
Cholesterol, AST, GGT and triglyceridesNo significant change markedNo baseline-comparison asterisks on these rows.
Reported adverse effectsNone reportedObservation was short. The report provides no structured adverse-event table.
Tables 2–3 · selected chronic-hepatitis measurements
Tables 2–3 · selected chronic-hepatitis measurements
MeasureBaseline columnUsual careUsual care + Ovagen
Bilirubin (µmol/L)28.4 ± 0.526.4 ± 1.121.5 ± 0.7*
ALT (unit unclear)50.2 ± 3.244.3 ± 3.1*41.4 ± 2.8*
AST (unit unclear)38.6 ± 2.140.2 ± 2.236.1 ± 2.5
IgM (g/L)3.6 ± 0.032.5 ± 0.08*2.1 ± 0.03*
IgG (g/L)14.0 ± 1.214.2 ± 1.014.1 ± 1.1

Asterisks are from the source and indicate p < 0.05 versus the pretreatment value. The type of ± term is unspecified.

The shared baseline and unspecified allocation prevent a reliable estimate of an effect attributable to Ovagen.

Source for these results ↗ · Reviewed 2026-11-13

Study limitations and source details

Study limitations

  • The report provides a shared baseline column and omits comparator subgroup sizes and allocation methods. Significance markers compare values with baseline.
  • The 2011 compilation reproduces a 2005–2006 study and does not authenticate the protocol or establish that this product was the EDL sequence tested in kidney models.

Source details

Institute report — commercial reproduction

Russian commercial reproduction of the 2011 institute report, methods and Tables 1–3

Sources checked

Added to the library

Citation

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Human comparative studyFull text available

A. A. Veretenko, O. Yu. Raigorodskii. Oral Ovagen in chronic hepatitis and after chemotherapy St. Petersburg Institute of Bioregulation and Gerontology Medical Center report (commercial reproduction)

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards